Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...

The second-most common cancer in Malaysia may not have symptoms, which is why experts advocate checkups for early detection.

Among 997 patients with lung cancer, only 35.1% met USPSTF screening criteria, while universal age-based screening (40-85 ...

A new study shows that many adults who are eligible for lung cancer screening are skipping it, but experts say it could mean ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share. Click here ...

Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer ...

Abbott Laboratories, headquartered in north suburban Abbott Park, will acquire Madison, Wisconsin-based Exact Sciences, the ...

Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

Chinese scientists may have developed a possible alternative to colonoscopies for detecting gastrointestinal diseases with a ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.